Cytokinetics, Incorporated

NasdaqGS:CYTK Stock Report

Market Cap: US$6.1b

Cytokinetics Valuation

Is CYTK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CYTK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$228.44
Fair Value
77.6% undervalued intrinsic discount
17
Number of Analysts

Below Fair Value: CYTK ($51.13) is trading below our estimate of fair value ($228.44)

Significantly Below Fair Value: CYTK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CYTK?

Key metric: As CYTK barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CYTK. This is calculated by dividing CYTK's market cap by their current book value.
What is CYTK's PB Ratio?
PB Ratio-16.6x
Book-US$368.72m
Market CapUS$6.12b

Price to Book Ratio vs Peers

How does CYTK's PB Ratio compare to its peers?

The above table shows the PB ratio for CYTK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average3.1x
MRNA Moderna
1x36.55%US$9.1b
XENE Xenon Pharmaceuticals
4.4x24.14%US$2.8b
RVMD Revolution Medicines
4.7x22.63%US$8.7b
IDYA IDEAYA Biosciences
2.2x17.17%US$2.2b
CYTK Cytokinetics
n/a38.98%US$6.1b

Price-To-Book vs Peers: CYTK has negative equity and a Price-To-Book Ratio (-16.6x) compared to the peer average (3.1x).

Price to Book Ratio vs Industry

How does CYTK's PB Ratio compare vs other companies in the US Biotechs Industry?

62 CompaniesPrice / BookEstimated GrowthMarket Cap
TRDA Entrada Therapeutics
0.5x-22.89%US$187.72m
NKTX Nkarta
0.4x1.69%US$139.92m
FATE Fate Therapeutics
0.4x-1.49%US$111.07m
ZNTL Zentalis Pharmaceuticals
0.4x13.87%US$107.48m
CYTK is unprofitableIndustry Avg. 2.2xNo. of Companies82PB0246810+
62 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CYTK has negative equity and a Price-To-Book Ratio (-16.6x) compared to the US Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is CYTK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CYTK PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-16.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CYTK's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CYTK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$51.13
US$74.41
+45.53%
26.54%US$120.00US$41.00n/a17
Sep ’26US$35.33
US$71.05
+101.11%
27.14%US$120.00US$41.00n/a19
Aug ’26US$36.69
US$72.11
+96.53%
28.48%US$120.00US$41.00n/a19
Jul ’26US$33.64
US$72.55
+115.67%
27.71%US$120.00US$41.00n/a20
Jun ’26US$31.02
US$73.45
+136.78%
26.69%US$120.00US$41.00n/a20
May ’26US$42.92
US$77.19
+79.85%
23.70%US$120.00US$47.00n/a21
Apr ’26US$37.50
US$78.40
+109.07%
21.58%US$120.00US$47.00n/a20
Mar ’26US$46.00
US$79.10
+71.96%
20.05%US$120.00US$60.00n/a20
Feb ’26US$49.46
US$81.61
+65.00%
19.86%US$120.00US$60.00n/a18
Jan ’26US$47.04
US$81.71
+73.69%
20.41%US$120.00US$60.00n/a17
Dec ’25US$51.86
US$80.56
+55.35%
20.69%US$120.00US$60.00n/a16
Nov ’25US$51.82
US$83.06
+60.28%
21.13%US$120.00US$60.00n/a17
Oct ’25US$52.60
US$81.29
+54.55%
18.55%US$107.00US$60.00n/a17
Sep ’25US$57.08
US$80.94
+41.80%
19.01%US$107.00US$60.00US$35.3317
Aug ’25US$57.91
US$82.65
+42.72%
16.79%US$107.00US$60.00US$36.6917
Jul ’25US$54.70
US$82.65
+51.09%
16.79%US$107.00US$60.00US$33.6417
Jun ’25US$48.51
US$85.12
+75.46%
18.79%US$122.00US$60.00US$31.0217
May ’25US$63.37
US$90.28
+42.47%
20.60%US$122.00US$42.40US$42.9219
Apr ’25US$73.02
US$92.07
+26.09%
19.27%US$122.00US$42.40US$37.5019
Mar ’25US$73.98
US$92.13
+24.53%
19.21%US$122.00US$42.40US$46.0019
Feb ’25US$81.25
US$92.18
+13.45%
19.21%US$122.00US$42.40US$49.4619
Jan ’25US$83.49
US$82.97
-0.62%
24.15%US$110.00US$42.40US$47.0419
Dec ’24US$33.57
US$59.97
+78.64%
16.08%US$80.00US$41.00US$51.8620
Nov ’24US$35.10
US$61.29
+74.63%
14.75%US$80.00US$41.00US$51.8217
Oct ’24US$29.46
US$60.81
+106.42%
15.34%US$80.00US$41.00US$52.6016
Sep ’24US$36.00
US$60.81
+68.92%
15.34%US$80.00US$41.00US$57.0816
AnalystConsensusTarget
Consensus Narrative from 17 Analysts
US$74.41
Fair Value
31.3% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/14 14:01
End of Day Share Price 2025/09/12 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Carter GouldBarclays
Jason ZemanskyBofA Global Research